Early Evidence of Cardiotoxicity and Tumor Response in Patients with Sarcomas after High Cumulative Dose Doxorubicin Given as a Continuous Infusion

BACKGROUND: Despite the dose-dependent response rate of sarcomas to doxorubicin, clinicians limit its cumulative dose due to cardiotoxicity. This study evaluates early evidence of cardiotoxicity in patients treated with high-dose doxorubicin given as a continuous infusion. METHODS: Data was collecte...

Descripción completa

Detalles Bibliográficos
Autores principales: Quintana, Raymundo A., Banchs, Jose, Gupta, Ridhi, Lin, Heather Y., Raj, Sean D., Conley, Anthony, Ravi, Vinod, Araujo, Dejka, Benjamin, Robert S., Patel, Shreyaskumar, Vadhan-Raj, Saroj, Somaiah, Neeta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5634608/
https://www.ncbi.nlm.nih.gov/pubmed/29081684
http://dx.doi.org/10.1155/2017/7495914

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5634608/
https://www.ncbi.nlm.nih.gov/pubmed/29081684
http://dx.doi.org/10.1155/2017/7495914

Ejemplares similares